Analyst Ratings for [GERN] Geron Corporation

2/27/25	Downgrades	Buy Neutral	X
GERN Geron B. Riley Securities
$3.50 $2
2/26/25	Downgrades	Buy Neutral	X
GERN Geron H.C. Wainwright
11/5/24	Initiated	Buy	X
GERN Geron H.C. Wainwright
$8
10/16/24	Initiated	Sector Outperform	X
GERN Geron Scotiabank
9/9/24	Initiated	Outperform	X
GERN Geron Leerink Partners
$7
4/30/24	Downgrades	Outperform Neutral	X
GERN Geron Robert W. Baird
$4.50
4/29/24	Initiated	Buy	X
GERN Geron TD Cowen
$10
3/15/24	Reiterated	Buy	X
GERN Geron Needham
$4 $5
9/12/23	Upgrades	Neutral Buy	X
GERN Geron Goldman
$4
3/28/23	Initiated	Neutral	X
GERN Geron Goldman
$3
10/28/22	Initiated	Outperform	X
GERN Geron Wedbush
$5
7/28/22	Resumed	Buy	X
GERN Geron B. Riley Securities
$4
11/2/21	Initiated	Outperform	X
GERN Geron Robert W. Baird
$4
2/18/21	Resumed	Buy	X
GERN Geron B. Riley Securities
$4
8/15/19	Initiated	Overweight	X
GERN Geron Cantor Fitzgerald
$4
4/9/19	Upgrades	Hold Buy	X
GERN Geron Needham
$3
1/31/19	Upgrades	Neutral Buy	X
GERN Geron B. Riley FBR
$1.50 $3.25
10/2/18	Downgrades	Buy Neutral	X
GERN Geron B. Riley FBR
$5.75 $1.50
7/5/18	Initiated	Buy	X
GERN Geron B. Riley FBR, Inc.
$5.75

GERN Geron Corporation

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.